Therapeutic angiogenesis: A case for targeted, regulated gene delivery

Keith A Webster

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Blood and vascular disorders underlie a plethora of pathological conditions and are the single most frequent cause of human disease. Eliminated or restricted blood flow to tissues as a result of vessel dysfunction results in the disruption of oxygen and nutrient delivery and the accumulation of waste metabolites. Cells cannot survive extended severe ischemia but may be able to adapt to a moderate condition where diffusion to and from bordering nonischemic regions sustain vital functions. Under this condition, secondary functions of affected cells are likely to be impaired and a new metabolic equilibrium is established, determined by the level of cross-diffusion. In tissues with a normally high metabolic turnover such as skeletal and cardiac muscle, ischemia causes hypoxia, acidosis, and depressed function (contractility). The treatment possibilities for tissue ischemia resulting from vascular disease are limited. Lipid-lowering agents may help slow the progression of vessel disease in some instances, but surgical reconstruction may be the only option in advanced stages, and even this is not always an option. An alternative and rather obvious strategy to treat ischemia is to activate endogenous angiogenic or vasculogenic pathways and stimulate revascularization of the tissue. The feasibility of such a strategy has now been established through the results of studies over the past decade and a new discipline called therapeutic angiogenesis has emerged. This review focuses on the application of therapeutic angiogenesis for treating peripheral limb ischemia and coronary artery diseases; the author traces the evidence supporting the feasibility of this treatment strategy, its current limitations, and possible directions.

Original languageEnglish
Pages (from-to)113-125
Number of pages13
JournalCritical Reviews in Eukaryotic Gene Expression
Volume10
Issue number2
StatePublished - Nov 23 2000

Fingerprint

Ischemia
Genes
Therapeutics
Acidosis
Vascular Diseases
Blood Vessels
Disease Progression
Coronary Artery Disease
Myocardium
Skeletal Muscle
Extremities
Oxygen
Lipids
Food

Keywords

  • Gene therapy
  • Hypoxia
  • Limb ischemia
  • Myocardial ischemia

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics

Cite this

Therapeutic angiogenesis : A case for targeted, regulated gene delivery. / Webster, Keith A.

In: Critical Reviews in Eukaryotic Gene Expression, Vol. 10, No. 2, 23.11.2000, p. 113-125.

Research output: Contribution to journalArticle

@article{af427a63336940899434d8f71aaeb1e2,
title = "Therapeutic angiogenesis: A case for targeted, regulated gene delivery",
abstract = "Blood and vascular disorders underlie a plethora of pathological conditions and are the single most frequent cause of human disease. Eliminated or restricted blood flow to tissues as a result of vessel dysfunction results in the disruption of oxygen and nutrient delivery and the accumulation of waste metabolites. Cells cannot survive extended severe ischemia but may be able to adapt to a moderate condition where diffusion to and from bordering nonischemic regions sustain vital functions. Under this condition, secondary functions of affected cells are likely to be impaired and a new metabolic equilibrium is established, determined by the level of cross-diffusion. In tissues with a normally high metabolic turnover such as skeletal and cardiac muscle, ischemia causes hypoxia, acidosis, and depressed function (contractility). The treatment possibilities for tissue ischemia resulting from vascular disease are limited. Lipid-lowering agents may help slow the progression of vessel disease in some instances, but surgical reconstruction may be the only option in advanced stages, and even this is not always an option. An alternative and rather obvious strategy to treat ischemia is to activate endogenous angiogenic or vasculogenic pathways and stimulate revascularization of the tissue. The feasibility of such a strategy has now been established through the results of studies over the past decade and a new discipline called therapeutic angiogenesis has emerged. This review focuses on the application of therapeutic angiogenesis for treating peripheral limb ischemia and coronary artery diseases; the author traces the evidence supporting the feasibility of this treatment strategy, its current limitations, and possible directions.",
keywords = "Gene therapy, Hypoxia, Limb ischemia, Myocardial ischemia",
author = "Webster, {Keith A}",
year = "2000",
month = "11",
day = "23",
language = "English",
volume = "10",
pages = "113--125",
journal = "Critical Reviews in Eukaryotic Gene Expression",
issn = "1045-4403",
publisher = "Begell House Inc.",
number = "2",

}

TY - JOUR

T1 - Therapeutic angiogenesis

T2 - A case for targeted, regulated gene delivery

AU - Webster, Keith A

PY - 2000/11/23

Y1 - 2000/11/23

N2 - Blood and vascular disorders underlie a plethora of pathological conditions and are the single most frequent cause of human disease. Eliminated or restricted blood flow to tissues as a result of vessel dysfunction results in the disruption of oxygen and nutrient delivery and the accumulation of waste metabolites. Cells cannot survive extended severe ischemia but may be able to adapt to a moderate condition where diffusion to and from bordering nonischemic regions sustain vital functions. Under this condition, secondary functions of affected cells are likely to be impaired and a new metabolic equilibrium is established, determined by the level of cross-diffusion. In tissues with a normally high metabolic turnover such as skeletal and cardiac muscle, ischemia causes hypoxia, acidosis, and depressed function (contractility). The treatment possibilities for tissue ischemia resulting from vascular disease are limited. Lipid-lowering agents may help slow the progression of vessel disease in some instances, but surgical reconstruction may be the only option in advanced stages, and even this is not always an option. An alternative and rather obvious strategy to treat ischemia is to activate endogenous angiogenic or vasculogenic pathways and stimulate revascularization of the tissue. The feasibility of such a strategy has now been established through the results of studies over the past decade and a new discipline called therapeutic angiogenesis has emerged. This review focuses on the application of therapeutic angiogenesis for treating peripheral limb ischemia and coronary artery diseases; the author traces the evidence supporting the feasibility of this treatment strategy, its current limitations, and possible directions.

AB - Blood and vascular disorders underlie a plethora of pathological conditions and are the single most frequent cause of human disease. Eliminated or restricted blood flow to tissues as a result of vessel dysfunction results in the disruption of oxygen and nutrient delivery and the accumulation of waste metabolites. Cells cannot survive extended severe ischemia but may be able to adapt to a moderate condition where diffusion to and from bordering nonischemic regions sustain vital functions. Under this condition, secondary functions of affected cells are likely to be impaired and a new metabolic equilibrium is established, determined by the level of cross-diffusion. In tissues with a normally high metabolic turnover such as skeletal and cardiac muscle, ischemia causes hypoxia, acidosis, and depressed function (contractility). The treatment possibilities for tissue ischemia resulting from vascular disease are limited. Lipid-lowering agents may help slow the progression of vessel disease in some instances, but surgical reconstruction may be the only option in advanced stages, and even this is not always an option. An alternative and rather obvious strategy to treat ischemia is to activate endogenous angiogenic or vasculogenic pathways and stimulate revascularization of the tissue. The feasibility of such a strategy has now been established through the results of studies over the past decade and a new discipline called therapeutic angiogenesis has emerged. This review focuses on the application of therapeutic angiogenesis for treating peripheral limb ischemia and coronary artery diseases; the author traces the evidence supporting the feasibility of this treatment strategy, its current limitations, and possible directions.

KW - Gene therapy

KW - Hypoxia

KW - Limb ischemia

KW - Myocardial ischemia

UR - http://www.scopus.com/inward/record.url?scp=0033758113&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033758113&partnerID=8YFLogxK

M3 - Article

C2 - 11186327

AN - SCOPUS:0033758113

VL - 10

SP - 113

EP - 125

JO - Critical Reviews in Eukaryotic Gene Expression

JF - Critical Reviews in Eukaryotic Gene Expression

SN - 1045-4403

IS - 2

ER -